Assembly Biosciences, Inc.
ASMB
$34.60
-$1.50-4.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.19M | 33.25M | 32.15M | 28.52M | 28.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.19M | 33.25M | 32.15M | 28.52M | 28.33M |
| Cost of Revenue | 61.84M | 58.77M | 58.91M | 55.93M | 52.66M |
| Gross Profit | -24.65M | -25.52M | -26.75M | -27.41M | -24.33M |
| SG&A Expenses | 18.80M | 18.00M | 17.88M | 18.01M | 22.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.64M | 76.77M | 76.79M | 73.94M | 74.77M |
| Operating Income | -43.45M | -43.52M | -44.63M | -45.42M | -46.44M |
| Income Before Tax | -38.62M | -39.04M | -39.59M | -39.85M | -40.37M |
| Income Tax Expenses | -76.00K | -76.00K | 330.00K | 330.00K | 439.00K |
| Earnings from Continuing Operations | -38.55 | -38.96 | -39.92 | -40.18 | -40.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.55M | -38.96M | -39.92M | -40.18M | -40.80M |
| EBIT | -43.45M | -43.52M | -44.63M | -45.42M | -46.44M |
| EBITDA | -43.32M | -43.39M | -44.50M | -45.29M | -46.26M |
| EPS Basic | -4.81 | -5.60 | -6.25 | -6.73 | -7.21 |
| Normalized Basic EPS | -3.02 | -3.51 | -3.87 | -4.17 | -4.45 |
| EPS Diluted | -4.81 | -5.60 | -6.25 | -6.73 | -7.21 |
| Normalized Diluted EPS | -3.02 | -3.51 | -3.87 | -4.17 | -4.45 |
| Average Basic Shares Outstanding | 34.38M | 28.05M | 26.04M | 24.01M | 22.80M |
| Average Diluted Shares Outstanding | 34.38M | 28.05M | 26.04M | 24.01M | 22.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |